RANI
Rani Therapeutics Holdings Inc
NASDAQ: RANI · HEALTHCARE · BIOTECHNOLOGY
$0.94
+5.87% today
Updated 2026-05-01
Market cap
$108.42M
P/E ratio
—
P/S ratio
66.39x
EPS (TTM)
$-0.45
Dividend yield
—
52W range
$0 – $4
Volume
1.1M
Rani Therapeutics Holdings Inc (RANI) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $979000.00 | $462000.00 | $2.72M | $0.00 | $0.00 | $1.03M | $1.63M |
| Revenue growth (YoY) | — | -52.8% | +488.1% | -100.0% | — | — | +58.9% |
| Cost of revenue | — | — | — | $1.31M | $822000.00 | — | $900000.00 |
| Gross profit | $979000.00 | $462000.00 | $2.72M | $-1.31M | $-822000.00 | $1.03M | $733000.00 |
| Gross margin | 100.0% | 100.0% | 100.0% | — | — | 100.0% | 44.9% |
| R&D | $24.58M | $12.04M | $26.48M | $36.61M | $39.62M | $26.68M | $20.20M |
| SG&A | $3.46M | $4.96M | $27.83M | $26.84M | $26.48M | $23.95M | $19.74M |
| Operating income | $-27.07M | $-16.54M | $-51.60M | $-63.45M | $-66.10M | $-53.31M | $-38.31M |
| Operating margin | -2764.6% | -3581.0% | -1899.1% | — | — | -5186.2% | -2346.0% |
| EBITDA | $-26.01M | $-15.96M | $-52.08M | $-61.66M | $-65.28M | $-50.52M | $-37.41M |
| EBITDA margin | -2657.1% | -3453.5% | -1917.0% | — | — | -4914.7% | -2290.9% |
| EBIT | $-26.58M | $-16.54M | $-52.58M | $-62.20M | $-66.10M | $-51.55M | $-38.31M |
| Interest expense | $10000.00 | $124000.00 | $466000.00 | $1.07M | $5.08M | $5.03M | $2.89M |
| Income tax | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-26.60M | $-16.70M | $-8.33M | $-30.59M | $-33.97M | $-30.02M | $-29.67M |
| Net income growth (YoY) | — | +37.2% | +50.1% | -267.2% | -11.1% | +11.6% | +1.1% |
| Profit margin | -2716.8% | -3615.4% | -306.6% | — | — | -2920.0% | -1817.1% |